Navigation Links
Senetek PLC Reports 2008 Financial Results
Date:3/31/2009

Media Attention Builds for Pyratine-6(TM) and Pyratine XR(TM)

NAPA, Calif., March 31 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, announced results for the fourth quarter and year ended December 31, 2008.

Revenue for the year ended December 31, 2008 was $1,845,000, compared with $26,471,000 reported in 2007. Revenues for the fourth quarter of 2008 were $230,000, compared with $223,000 for the same period in the prior year.

Net loss for the year ended December 31, 2008 totaled $3,759,000 or $0.49 per diluted share compared to net income of $18,632,000 or $2.41 per diluted share in 2007. Net loss for the fourth quarter of 2008 was $1,209,000, or $0.16 per diluted share compared with net loss of $1,706,000, or $0.22 per diluted share in the fourth quarter of 2007.

Cash used in operations for the year ended December 31, 2008 was $3,971,000, compared with cash provided by operations of $18,019,000 in 2007.

Revenues, net income and cash flow in 2007 reflect the effect of the grant of a paid up license for Kinetin and Zeatin to Valeant Pharmaceuticals Inc. in March 2007 which contributed $24,750,000 to skincare revenues.

The Company continues to garner media attention related to its September 2008 launch of Pyratine-6(TM) and its March 2009 launch of Pyratine XR(TM) at the American Academy of Dermatology's 67th Annual Meeting. Pyratine-6(TM) and Pyratine XR(TM) have been featured in magazines including Prevention, Dermatology Times, Inside Cosmeceuticals, Les Nouvelles Esthetiques and Skin Inc. and in radio and television spots in Las Vegas, Nevada and Baltimore, Maryland.

Commenting on media coverage of Pyratine-6(TM) and Pyratine XR(TM), Frank J. Massino, Chairman and Chief Executive Officer of Senetek PLC stated "The high-profile consumer and trade media placements for Pyratine-6(TM) and Pyratine XR(TM) have raised product and brand visibility in the medical community, as well as directly with consumers, increasing product awareness and demand. With additional media coverage slated for early 2009 and an ongoing public relations campaign, we are confident that Pyratine-6(TM) and Pyratine XR(TM) will attain the success we know is possible."

About Senetek PLC:

Senetek PLC (OTCBB:SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin, the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's websites www.senetekplc.com www.pyratine-6.com www.pyratinexr.com

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Senetek PLC Reports Third Quarter 2007 Financial Results
2. Senetek PLC Announces Debut of Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology
3. Senetek PLC Announces Launch of New Website
4. Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts
5. Senetek PLC Reports 2007 Financial Results
6. Senetek PLC Announces Key Personnel Appointments
7. Senetek PLC Resolves Dispute With Marketer of Pyratine-6(TM) on Most Favorable Terms
8. Senetek Announces Plan for Promotion, Sales and Distribution of Pyratine-6(TM)
9. Senetek Announces Termination of Invicorp(R) License Agreement With Ardana Bioscience Limited
10. Dynamics Group AG Publishes Research Report on Senetek
11. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 top five ... art competition. Selected from 15 submissions from around the nation, the top five finalists ... iaedp Symposium, March 22 – 26 in Las Vegas. , This year, the competition ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... specializes in thought leadership , media relations, social media, content marketing and ... will be powered through Act-On, an intuitive marketing automation platform. , Rosica will ...
(Date:2/23/2017)... Austin, TX (PRWEB) , ... February 23, 2017 ... ... has announced an official 2017 partnership with The Jensie Gran Fondo of Marin. ... UVA and UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... return to the La Gorce Country Club in Miami Beach to host its ...
(Date:2/23/2017)... ... 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will ... to Hot,” which will begin airing on February 24, 2017. The show chronicles the ... 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from TLC ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017 Report analyzes the ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin ... forecasts are provided for the period 2015 through 2022. Also, ... data and analytics are derived from primary and secondary research. ...
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market Pty ... have joined forces, resulting in the founding of Pharma To Market ... Pharma To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... of the Singapore based entity. Joelle brings ...
(Date:2/24/2017)... Feb. 23, 2017  The particle counters market ... 2021 from USD 275.9 million in 2016, at ... full report: http://www.reportlinker.com/p04718602-summary/view-report.html The ... pharmaceutical R&D, and growth in manufacturing industries in ... growth for particle counters. On the other hand, ...
Breaking Medicine Technology: